The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor

  • Yim, Eunjung (Department of Internal Medicine, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea) ;
  • An, Ho Jung (Department of Internal Medicine, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea) ;
  • Cho, Uiju (Department of Pathology, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea) ;
  • Kim, Youngwoo (Department of Internal Medicine, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea) ;
  • Kim, Seung Hoon (Department of Internal Medicine, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea) ;
  • Choi, Yeon-Geun (Department of Internal Medicine, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea) ;
  • Shim, Byoung Yong (Department of Internal Medicine, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea)
  • Received : 2015.08.31
  • Accepted : 2015.10.15
  • Published : 2018.03.01
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130:1466-1478.
  2. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-4349. https://doi.org/10.1200/JCO.2003.04.190
  3. Andersson J, Sjogren H, Meis-Kindblom JM, Stenman G, Aman P, Kindblom LG. The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 2002;160:15-22. https://doi.org/10.1016/S0002-9440(10)64343-X
  4. Corless CL, McGreevey L, Town A, et al. KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors. J Mol Diagn 2004;6:366-370. https://doi.org/10.1016/S1525-1578(10)60533-8
  5. Dufresne A, Alberti L, Brahmi M, et al. Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology. BMC Cancer 2014;14:632. https://doi.org/10.1186/1471-2407-14-632

Cited by

  1. Gastrointestinal stromal tumor - A review of clinical studies vol.25, pp.6, 2019, https://doi.org/10.1177/1078155219846955
  2. Molecular exploration of paediatric intracranial germinomas from multi-ethnic Singapore vol.20, pp.1, 2020, https://doi.org/10.1186/s12883-020-01981-0
  3. Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-wor vol.21, pp.1, 2018, https://doi.org/10.1186/s12885-021-08013-1